Navigation Links
Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
Date:9/14/2007

completed a licensing and distribution agreement for Israel for its once-daily tramadol product with Dexcel Pharma Technologies Ltd. Under the terms of the agreement, Dexcel will have the exclusive right to market and sell Labopharm's once-daily tramadol product in Israel. Labopharm will supply Dexcel with product and will receive revenue at rates commensurate with those of previous licensing and distribution agreements that Labopharm has entered into for European markets. Labopharm will also receive an up front payment.

Dexcel (a Dexxon Company) is a research-based international specialty pharmaceutical company dedicated to treating and preventing human disease through discovery, development, manufacturing and commercialization of innovative pharmaceutical products based on sophisticated proprietary controlled-release oral solid dosage form drug delivery technologies. Dexcel's products treat conditions in the largest therapeutic markets, including Cardiovascular (CVS), Gastroenterology (GE), Central Nervous System (CNS) and Dental Health Care. The company markets more than 65 products in more than 170 dosages.

Labopharm's once-daily formulation of tramadol is currently under regulatory review in Israel. The Company expects a response from the Israeli regulatory authority by mid-2008.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http:
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
...developed a way to produce blood vessels by engine... Researchers at the University at Buffalo D...y that the bone marrow is an excellent source of a... applications. According to Dr. Stelios T....
...e University of Nottingham are amassing an arsenal... against the most deadly of hospital superbugs . .... Its defences are so strong it can resist most an...hcare Associated Infections (CHAI), with Dr Peter ...
...niversity researcher is experimenting with ways to...hat we like about our favourite snacks . S...nce and industry at K-State's College of Agricultu... this process can be used to make fibre-enriched f...
...found that women are the real bosses at home . ...s, wives have greater power in marriage problem-so... 72 married couples from Iowa, found that wives, o... not considering who raised the topic. As...
...ting dads will be given some tips on how to raise ... The British government is hoping that its 23milli...et technology to support parents will appeal to fa...w initiative, "Parent Know-How", parents will be a...
...ho killed his 25-year-old female neighbor was sent...of Alicia Ross by her neighbor Daniel Sylvester w...ousness, by an Ontario Superior Court judge who im...er in the death of Alicia Ross, intended to kill h...
Other Medicine News:Health News:New Blood Vessels can Be Created from Bone Marrow Stem Cells: Study 2Health News:The Hospital Superbugs 2Health News:The Hospital Superbugs 3Health News:Now, Fibre-enriched Tasty Snacks in the Making 2Health News:Women are the Real Bosses at Home 2Health News:Women are the Real Bosses at Home 3Health News:A Savage Murderer in Canada Gets Sentenced to Life 2
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
(Date:12/4/2009)BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: VOLC ), today announced the initial development and successful testing of a novel integra
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Omega 3 fatty acids appear to impact AMD progression 8896 1Omega 3 fatty acids appear to impact AMD progression 8896 2Omega 3 fatty acids appear to impact AMD progression 8896 3The Leukemia 26 Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 49377 1The Leukemia 26 Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 49377 2Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 1Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 2Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 3
... SUNNYVALE, Calif., April 13 Pharmacyclics, In...egun treating patients in a Phase,1 dose-escalatio... PCI-32765,an orally available, selective inhibito...al treatment for patients with relapsed or refract... the first Btk selective inhibitor to,be tested in...
... NOVATO, Calif., April 13 Raptor Pharmaceuticals ...ard: RPTP) today announced the appointment of Patr...r ("CMO"). Dr. Rioux will be responsible for the c...nical-stage drug development programs. , , (Logo:...YM074LOGO ) , , Raptor,s clinical programs inc...
Other Medicine Technology:Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 2Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 3Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 4Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 5
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
Medicine Products: